SolasCure
Biotechnology ResearchView the employees at
SolasCure-
David Fairlamb Regulatory Affairs Director at SolasCure
-
East Morton, England, United Kingdom
-
Top 5%
Louise Bradley Clinical Supply Chain Manager at SolasCure-
Belfast Metropolitan Area
-
Rising Star
Kinga Szepeshazi, Dr. Chief Development Officer/Medical Director at SolasCure-
United Kingdom
-
Rising Star
Adam Rytko Quality Assurance Consultant, GCP/GDP/GCLP Auditor-
Warsaw, Mazowieckie, Poland
-
Rising Star
Jane Hart, MBA, B.App.Sci Hons VP, Clinical Operations at LumaBridge-
San Antonio, Texas Metropolitan Area
-
Top 10%
Overview
Leveraging biomimicry and evidence-based medicine, SolasCure is a pioneering biologics company developing its first investigational product, Aurase Wound Gel, a hydrogel containing an enzyme cloned from medical maggots, which aims to accelerate debridement of chronic wounds. Through developing its innovative debridement technology, SolasCure aims to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds in an outpatient or home setting. SolasCure was founded in 2017 as a spin-off from BRAIN Biotech AG, a leading German biotech company focused on harnessing biological diversity to develop innovative solutions. SolasCure is headquartered in Cambridge, UK.
-